A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06162299
- Locations
- 🇵ðŸ‡
Iloilo Doctors' Hospital, Iloilo, Philippines
A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried
Phase 3
Active, not recruiting
- Conditions
- RabiesPrevention
- Interventions
- Biological: PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-driedBiological: Chirorab
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 4500
- Registration Number
- NCT05667974
- Locations
- 🇵ðŸ‡
PGH, Manila, Philippines
🇵🇰Al-Shifa Trust Eye Hospital, Islamabad, Pakistan
🇵🇰Ziauddin University, Karachi, Pakistan
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
Phase 2
Completed
- Conditions
- Covid-19 Vaccine
- Interventions
- Biological: Inactivated Covid-19 vaccineBiological: PIKA COVID-19 vaccine
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 5860
- Registration Number
- NCT05463419
- Locations
- 🇵ðŸ‡
UERM Research Center, Quezon City, Philippines
🇵ðŸ‡St. John Hospital, Naga, Philippines
🇦🇪Al Kuwait Hospital, Dubai, United Arab Emirates
A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals
Phase 1
Completed
- Conditions
- COVID-19 Pandemic
- Interventions
- Biological: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm ABiological: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT05305300
- Locations
- 🇦🇪
Al Kuwait Hospital (Al Baraha Hospital), Dubai, United Arab Emirates
Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Biological: YS-0N-001
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT03131765
- Locations
- 🇸🇬
National University Cancer Institute Singapore, Singapore, Singapore
Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen
Phase 2
Completed
- Conditions
- Rabies
- Interventions
- Biological: PIKA rabies vaccineBiological: RABIPUR®
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT02956421
- Locations
- 🇸🇬
SingHealth Investigational Medicine Unit, Singapore, Singapore
🇸🇬Clinical Trials & Research Unit, Singapore, Singapore
Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant
Phase 1
Completed
- Conditions
- Rabies
- Interventions
- Biological: RABIPUR®Biological: PIKA rabies vaccine with an accelerated regimenBiological: PIKA rabies vaccine
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT02657161
- Locations
- 🇸🇬
SingHealth Investigational Medicine Unit, Singapore, Singapore
© Copyright 2025. All Rights Reserved by MedPath